الفهرس 
MULTIPLE MYELOMAOnly 14 pages are availabe for public view
 |  | from | 116 |  |  |
| | | from | 116 | | |
Abstract
Hepcidin-25, a 25-amino acid peptide primarily produced in the liver, is thought to be the central regulator of body iron metabolism. Since the clinical characteristics of the anemias of chronic inflammation are similar to anemia found in cancer, and since several tumor types are associated with increased cytokine production, especially hepcidin has been addressed as an explanation for the associated anemia in these conditions. The present study aimed to evaluate the role of hepcidin levels in a group of Egyptian patients including 12 patients with Hodgkin’s lymphoma (HL), 14 patients with non-Hodgkin’s lymphoma (NHL) and 24 patients with multiple myeloma (MM). Patients with each type of malignancy were equally divided into two groups: group I included patients anemic patients and group II included non-anemic patients. In the same group, hepcidin levels were significantly higher in anemic patients and had significant inverse correlation with hemoglobin levels. In addition, the present study found no statistically significant correlation between hepcidin levels and the other clinical and laboratory data. Similar to HL patients, there were significantly lower hepcidin levels in normal NHL patients when compared with anemic patients. Also, there was a significant inverse correlation between hepcidin levels and Hb levels but not with other clinical and laboratory data. Similar to the other two groups, there was significantly lower hepcidin levels in normal HL patients when compared with anemic patients.